ChemicalBook > CAS DataBase List > 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride

4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride

Product Name
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride
CAS No.
1646321-63-2
Chemical Name
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride
Synonyms
LNP023 hcl;EOS-61917;Iptacopan HCl;Iptacopan(lnp023);LNP023 hydrochloride;Iptacopanhydrochloride;Ipcoopam hydrochloride.;LNP023/Iptacopan hydrochloride;Iptacopan (LNP023) hydrochloride;Iptacopanhydrochloride，LNP023 hcl
CBNumber
CB53142722
Molecular Formula
C25H31ClN2O4
Formula Weight
458.98
MOL File
1646321-63-2.mol
More
Less

4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Property

storage temp. 
Store at -20°C
solubility 
DMSO : 250 mg/mL (544.69 mM; Need ultrasonic)|
form 
A solid
color 
White to off-white
Water Solubility 
Water : 50 mg/mL (108.94 mM; ultrasonic and warming and heat to 60°C)
InChIKey
SEZXOFFLNHXEJE-QHWHZDSMNA-N
SMILES
C(N1CC[C@H](OCC)C[C@H]1C1C=CC(C(=O)O)=CC=1)C1C(=CC(C)=C2NC=CC=12)OC.Cl |&1:4,9,r|
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-0131140
Product name
Iptacopan(hydrochloride)
Packaging
5mg
Price
$400
Updated
2021/12/16
ChemScene
Product number
CS-0131140
Product name
Iptacopan(hydrochloride)
Packaging
10mg
Price
$680
Updated
2021/12/16
ChemScene
Product number
CS-0131140
Product name
Iptacopan(hydrochloride)
Packaging
50mg
Price
$1900
Updated
2021/12/16
ChemScene
Product number
CS-0131140
Product name
Iptacopan(hydrochloride)
Packaging
100mg
Price
$2900
Updated
2021/12/16
More
Less

4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Chemical Properties,Usage,Production

Uses

LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. LNP023 inhibits factor B with an IC50 value of 10 nM[1][2].

in vivo

LNP023 (20-180 mg/kg; oral administration) prevents KRN (150 μL)-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats[2].
LNP023 exhibits moderate half-lives (T1/2; Wistar Han rats 3.4 h, beagle dogs 5.5 h) and Cmax (Wistar Han rats 410 nM, beagle dogs 2200 nM) following oral administration (rat 30 and, dog 10 mg/kg)[3].
LNP023 exhibits terminal elimination half-lives (T1/2; Wistar Han rats 7 h, beagle dogs 5.6 h) due to high plasma clearance (8, and 2 mL/min/kg respectively combined with large volumes of distribution (2.3, and 0.6 L/kg respectively) following intravenous administration (rat 1.0 and, dog 0.1 mg/kg)[3].

Animal Model:C57BL/6 mice with KRN-induced arthritis[2]
Dosage:20, 60, and 180 mg/kg
Administration:Orally gavaged; twice a day (b.i.d.) for 14 days
Result:Blocked KRN-induced arthritis.

References

[1] Dimitrios C Mastellos, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul;55(3):167-175. DOI:10.1053/j.seminhematol.2018.02.002
[2] Anna Schubart, et al. Small-molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931. DOI:10.1073/pnas.1820892116
[3] Nello Mainolfi, et al. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. DOI:10.1021/acs.jmedchem.9b01870

4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Suppliers

China 59 United States 5 Global 64
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Aladdin Scientific
Tel
Email
tp@aladdinsci.com
Country
United States
ProdList
52923
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354;
Email
support@targetmol.com
Country
United States
ProdList
39035
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81

1646321-63-2, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochlorideRelated Search:


  • 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride
  • EOS-61917
  • LNP023 hcl
  • LNP023 hydrochloride
  • Iptacopan(lnp023)
  • Iptacopanhydrochloride
  • Iptacopanhydrochloride，LNP023 hcl
  • Iptacopan HCl
  • Iptacopan (LNP023) hydrochloride
  • LNP 023,hemoglobinuria,inhibit,PNH,Iptacopan hydrochloride,atypical,pathogenesis,Inhibitor,LNP023,factor B,system,Iptacopan,Complement System,complement,paroxysmal,syndrome,LNP-023,pathway,hemolytic,uremic,alternative,nocturnal
  • 4-[(2S,4S)-4-Ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]benzoic acid,hydrochloride (1:1)
  • LNP023/Iptacopan hydrochloride
  • Ipcoopam hydrochloride.
  • Iptacopan hydrochloride, 10 mM in DMSO
  • -((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride
  • 1646321-63-2